AbbVie and AstraZeneca settle cancer drug patent suits

AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US biotech fires trade secrets suit at Chinese pharma group

10 June 2026 Valuable antibody technology, a former employee, and a dispute over patent rights extending across the US, Europe and Asia at the heart of the latest suit.

Americas

Hikma v Amarin: Six takeaways from the pivotal ruling

9 June 2026 A unanimous SCOTUS ruling is being hailed as a major win for Hikma, and for delivering some welcome clarity. Experts tell Marisa Woutersen how its implications could affect pharma patent strategy across the sector.

Americas

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

8 June 2026 Nexus Pharmaceuticals is knocked back by the US Court of Appeals, which upholds a district court finding that it infringed a rival’s patents.

More features

US biotech fires trade secrets suit at Chinese pharma group

Hikma v Amarin: Six takeaways from the pivotal ruling

Exclusive: ‘When a UPC judge wears their robe, they have no gender’

Clarivate’s new IP president to ‘usher in next phase of growth’

Fed Circ rejects Nexus’ appeal in generics row with biopharma firm

Ex-Kirkland patent litigator jumps to rival firm

Hikma triumphs at SCOTUS in landmark skinny-label ruling

Pfizer strikes $10.5 billion oncology deal with Chinese biotech

AbbVie and AstraZeneca settle cancer drug patent suits

More on this story

Editor's picks

Editor's picks

More features